Evoke Pharma Income After Taxes 2012-2024 | EVOK
Evoke Pharma income after taxes from 2012 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Evoke Pharma Annual Income After Taxes
(Millions of US $) |
| 2023 |
$-8 |
| 2022 |
$-8 |
| 2021 |
$-9 |
| 2020 |
$-13 |
| 2019 |
$-7 |
| 2018 |
$-8 |
| 2017 |
$-12 |
| 2016 |
$-11 |
| 2015 |
$-12 |
| 2014 |
$-13 |
| 2013 |
$-3 |
| 2012 |
$-2 |
| 2011 |
$-2 |
Evoke Pharma Quarterly Income After Taxes
(Millions of US $) |
| 2024-06-30 |
$-1 |
| 2024-03-31 |
$-2 |
| 2023-12-31 |
$-2 |
| 2023-09-30 |
$-2 |
| 2023-06-30 |
$-2 |
| 2023-03-31 |
$-2 |
| 2022-12-31 |
$-2 |
| 2022-09-30 |
$-2 |
| 2022-06-30 |
$-2 |
| 2022-03-31 |
$-2 |
| 2021-12-31 |
$-2 |
| 2021-09-30 |
$-2 |
| 2021-06-30 |
$-2 |
| 2021-03-31 |
$-3 |
| 2020-12-31 |
$-2 |
| 2020-09-30 |
$-2 |
| 2020-06-30 |
$-7 |
| 2020-03-31 |
$-2 |
| 2019-12-31 |
$-1 |
| 2019-09-30 |
$-2 |
| 2019-06-30 |
$-2 |
| 2019-03-31 |
$-2 |
| 2018-12-31 |
$-2 |
| 2018-09-30 |
$-2 |
| 2018-06-30 |
$-2 |
| 2018-03-31 |
$-2 |
| 2017-12-31 |
$-0 |
| 2017-09-30 |
$-5 |
| 2017-06-30 |
$-2 |
| 2017-03-31 |
$-5 |
| 2016-12-31 |
$-2 |
| 2016-09-30 |
$-3 |
| 2016-06-30 |
$-3 |
| 2016-03-31 |
$-3 |
| 2015-12-31 |
$-3 |
| 2015-09-30 |
$-3 |
| 2015-06-30 |
$-3 |
| 2015-03-31 |
$-4 |
| 2014-12-31 |
$-3 |
| 2014-09-30 |
$-4 |
| 2014-06-30 |
$-4 |
| 2014-03-31 |
$-3 |
| 2013-12-31 |
$-2 |
| 2013-09-30 |
$-0 |
| 2013-06-30 |
$-0 |
| 2013-03-31 |
$-0 |
| 2012-12-31 |
|
| 2012-09-30 |
$-0 |
| 2012-06-30 |
|
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.004B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
